24 positions · $148M portfolio reported
636 positions · $150M portfolio reported
20 positions · $126M portfolio reported
24 positions · $160M portfolio reported
127 positions · $211M portfolio reported
36 positions · $149M portfolio reported
17 positions · $137M portfolio reported
20 positions · $139M portfolio reported
1,916 positions · $21.5B portfolio reported
66 positions · $192M portfolio reported
152 positions · $173M portfolio reported
467 positions · $2.5B portfolio reported
197 positions · $6.8B portfolio reported
1,037 positions · $1.0B portfolio reported
48 positions · $310M portfolio reported
582 positions · $3.1B portfolio reported
Passive 8.0% disclosure in PSB Financial, Inc.
Passive 10.5% disclosure in Jin Medical International Ltd.
Amendment to 13D — 0.2% in Cerebras Systems, Inc.
Amendment to 13D — 28.5% in World Acceptance Corporation
21.8% stake in Katapult Holdings, Inc. · The information set forth in Items 3 and 6 is incorporated by reference in its entirety into this Item 4. On December 11, 2025, the Issuer entered into the Merger Agreement with Merger Sub 1, Merger Sub 2, CCFI, and Aaron's. Pursuant to the Merger Agreement, on August 11, 2026, (i) Merger Sub 1 merged with and into Aaron's, with Aaron's surviving as a wholly owned subsidiary of the Issuer (the "Aaron's Merger"), and (ii) Merger Sub 2 merged with and into CCFI, with CCFI surviving as a wholly owned subsidiary of the Issuer (the "CCFI Merger" and, together with the Aaron's Merger, the "Mergers"). The Mergers were effected as all-stock transactions. No cash consideration was paid. Pursuant to the Merger Agreement, each outstanding equity interest in CCFI (other than certain excluded interests) was converted into the right to receive shares of Common Stock of the Issuer based on the applicable exchange ratios set forth in the Merger Agreement. Similarly, each share of Aaron's common stock outstanding immediately prior to the effective time was converted into shares of Common Stock of the Issuer based on the applicable exchange ratio. Mr. Jones serves as Observer to the Board of Directors. William Jones III, the son of W. Allan Jones, serves as a member of the Board of Directors of the Issuer, having been designated as a Class C director pursuant to the Stockholders Agreement described in Item 6. As a result, the Reporting Persons may have influence over the corporate activities of the Issuer, including activities that may relate to items described in subparagraphs (a) through (j) of Item 4 of Schedule 13D. The Reporting Persons may, from time to time and subject to the Lock-Up Agreements described in Item 6, acquire additional securities of the Issuer either in the open market or in privately negotiated transactions, or dispose of all or a portion of their holdings, depending upon the Reporting Persons' evaluation of the Issuer's business, prospects and financial condition, the market for the Common Stock, other opportunities available to the Reporting Persons, general economic conditions, stock market conditions and other factors. Except as described in this Schedule 13D, the Reporting Persons do not have any present plans or proposals as of the date hereof that relate to or would result in any of the transactions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D.
Amendment to 13D — 0.0% in SunScout Holding Ltd
Amendment to 13D — 10.2% in Birkenstock Holding plc
27.5% stake in SunScout Holding Ltd · Any transaction described in this Item 4 is subject to the lock-up agreement described in Item 6, which restricts transfers of Class A Ordinary Shares and securities convertible into or exercisable or exchangeable for Class A Ordinary Shares until February 11, 2027, without the prior written consent of Dominari Securities LLC.
Amendment to 13D — 24.7% in KE Holdings Inc.
5.4% stake in Conexeu Sciences Inc. · The information set forth in Items 3, 5 and 6 of this Schedule 13D is incorporated by reference herein. Background On May 14, 2025, the Issuer and 1036030 B.C. Ltd., a company solely owned by the Reporting Person, entered into a consulting services agreement pursuant to which the Reporting Person was granted 2,000,000 Performance Warrants to acquire shares of Common Stock at an exercise price of $0.001 per share, with a term of five years. The Performance Warrants vest contingent upon the occurrence of the following four specified performance milestones: - Milestone 1: 500,000 Performance Warrants shall vest upon the Issuer completing and receiving the results of a three-month collagen study conducted in Boston, Massachusetts; - Milestone 2: 500,000 Performance Warrants shall vest upon the Issuer listing its shares of Common Stock on the Nasdaq Stock Market, LLC, or any other recognized stock exchange in North America; - Milestone 3: 500,000 Performance Warrants shall vest upon the Issuer's listed shares of Common Stock trading for at least 20 consecutive trading days at a market capitalization of $80,000,000 or greater on a recognized North American stock exchange on which the shares of Common Stock are listed; and - Milestone 4: 500,000 Performance Warrants shall vest upon the Issuer's submission of a 510(k) application to the U.S. Food and Drug Administration. On July 8, 2025, Milestone 1 was achieved upon the Issuer completing and receiving the results of the three-month collagen study, resulting in the vesting of 500,000 Performance Warrants with respect to Milestone 1. On December 23, 2025, the Reporting Person exercised the vested 500,000 Performance Warrants in full, acquiring 500,000 shares of Common Stock at an exercise price of $0.001 per share, for aggregate consideration of $500.00 funded from the Reporting Person's personal funds. The Reporting Person's beneficial ownership in the Performance Warrants was previously reported in the Issuer's Registration Statement on Form S-1/A filed with the Securities and Exchange Commission (the "SEC") on April 17, 2026, which included (i) 500,000 shares of Common Stock held directly by Mr. Sharpe, and (ii) 500,000 Performance Warrants that were to vest upon the occurrence of the listing milestone as part of the Reporting Person's beneficial ownership at such time. On May 21, 2026, the date of the Issuer's listing on the Nasdaq, 500,000 Performance Warrants held by the Reporting Person vested upon the occurrence of the listing milestone. On May 22, 2026, the Reporting Person exercised 500,000 Performance Warrants at an exercise price of $0.001 per share, for aggregate proceeds to the Issuer of $500.00, resulting in the issuance of 500,000 shares of Common Stock to the Reporting Person. On June 18, 2026, an additional 500,000 Performance Warrants held by the Reporting Person vested upon the Issuer's achievement of a market capitalization of $80,000,000 or greater for at least 20 consecutive trading days on the Nasdaq. This Schedule 13D is being filed to report the Reporting Person's updated beneficial ownership following the vesting of the June 2026 Vested Warrants. Purpose The Reporting Person acquired the securities described herein in connection with his compensation arrangements with the Issuer. The Reporting Person currently holds the shares of Common Stock and the Performance Warrants for investment purposes. The Reporting Person reserves the right to formulate other plans or make other proposals and take other actions with respect to his interest in the Issuer. Depending on market conditions and other factors, the Reporting Person may acquire or dispose of securities of the Issuer as the Reporting Person may deem appropriate, whether in open market purchases or sales, privately negotiated transactions or otherwise. The Reporting Person continues to evaluate numerous potential transactions and in connection therewith may exchange shares of Common Stock for other assets or may sell shares of Common Stock to increase his cash position. The Reporting Person may also reconsider and change his plans or proposals relating to the foregoing. Except as otherwise disclosed herein, the Reporting Person has no current plans or proposals that relate to or would result in any of the actions specified in clauses (a) through (j) of Item 4 of Schedule 13D.
Amendment to 13D — 4.9% in HUMACYTE, INC.
Amendment to 13D — 48.3% in YY Group Holding Limited
Passive 10.3% disclosure in Addentax Group Corp.
Amendment to 13D — 6.1% in Ensysce Biosciences, Inc.
Passive 9.9% disclosure in Edgemode, Inc.
Amendment to 13G — 5.7% in Kartoon Studios Inc
23.2% stake in SunScout Holding Ltd · Any transaction described in this Item 4 is subject to the lock-up agreement described in Item 6, which restricts transfers of Class A Ordinary Shares and securities convertible into or exercisable or exchangeable for Class A Ordinary Shares until February 11, 2027 without the prior written consent of Dominari Securities LLC.
Amendment to 13G — 2.0% in GENERATION INCOME PROPERTIES, INC.
47.8% stake in Advasa Holdings, Inc. · Mr. Kosugi received the 232,638,232 shares of the Issuer's common stock, pursuant to a share exchange agreement between the Issuer and Advasa, Co., Ltd. ("Advasa Japan") and Advasa Japan's shareholders, pursuant to which the Issuer acquired 96.6% ownership interest in Advasa Japan from Advasa Japan's shareholders (one of which was the Reporting Person) in exchange for shares of the Issuer. The Reporting Person from time to time intends to review their investments in the Issuer on the basis of various factors, including the Issuer's business, financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in general and those for the Issuer's common stock shares in particular, as well as other developments and other investment opportunities. Based upon such review, the Reporting Person may take such actions in the future as the Reporting Person may deem appropriate in light of the circumstances existing from time to time. If the Reporting Person believes that further investment in the Issuer is attractive, whether because of the market price of the common stock shares or otherwise, they may acquire common stock shares or other securities of the Issuer either in the open market or in privately negotiated transactions. Similarly, depending on market and other factors, the Reporting Person may determine to dispose of some or all of the common stock shares currently owned by the Reporting Person or otherwise acquired by the Reporting Person either in the open market or in privately negotiated transactions. Except as set forth in this Schedule 13D, the Reporting Person has not formulated any plans or proposals which relate to or would result in: (a) the acquisition by any person of additional securities of the Issuer or the disposition of securities of the Issuer; (b) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) a sale or transfer of a material amount of the assets of the Issuer or any of its subsidiaries; (d) any change in the present Board of Directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board; (e) any material change in the Issuer's capitalization or dividend policy of the Issuer; (f) any other material change in the Issuer's business or corporate structure; (g) any change in the Issuer's charter or bylaws or other instrument corresponding thereto or other action which may impede the acquisition of control of the Issuer by any person; (h) causing a class of the Issuer's securities to be deregistered or delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; (i) a class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Act; or (j) any action similar to any of those enumerated above.
Amendment to 13G — 4.2% in CoastalSouth Bancshares, Inc.
Purchase · 10,600 shares · $4.93
Purchase · 10,000 shares · $11.03
Sale · 2,000 shares · $375.00
Purchase · 9,000 shares · $5.54